Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30515527 | 0.80 | IDO1 (0.34) | IDO1 | |
| SCHEMBL14060842 | 0.80 | IDO1 (0.34) | IDO1 | |
| SCHEMBL25707543 | 0.78 | IDO1 (0.35) | IDO1 | |
| SCHEMBL15275552 | 0.77 | IDO1 (0.38) | IDO1 | |
| SCHEMBL16235522 | 0.77 | DAO (0.46) | — | |
| SCHEMBL3297906 | 0.71 | IDO1 (0.44) | IDO1 | |
| SCHEMBL14785048 | 0.71 | IDO1 (0.33) | IDO1 | |
| SCHEMBL10294709 | 0.71 | RAB9A (0.49) | IDO1 | |
| SCHEMBL29722898 | 0.71 | RAB9A (0.49) | IDO1 | |
| SCHEMBL14153123 | 0.71 | MAOB (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755948-B1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER IP GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| EP-2755948-B1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER IP GMBH (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9133171-B2 | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133171-B2 | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133171-B2 | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20150005329-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005329-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
| US-20150005329-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-01 | — | — | US | disclosed |
| EP-2755948-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | Bayer Intellectual Property GmbH (DE) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013037894-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037894-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005329-A1 | DISUBSTITUTED 5-FLUORO PYRIMIDINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP | DHFR, DPYD, TYMP | IDO1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.